{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:23:08Z","timestamp":1767151388536,"version":"build-2238731810"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":3371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/gim.2012.39","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T11:23:53Z","timestamp":1334229833000},"page":"779-786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)"],"prefix":"10.1016","volume":"14","author":[{"given":"Kazuya","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/gim.2012.39_bb0010","author":"Nagueh"},{"key":"10.1038\/gim.2012.39_bb0015","author":"Zarate"},{"key":"10.1038\/gim.2012.39_bb0020","author":"Fabry"},{"key":"10.1038\/gim.2012.39_bb0025","author":"Mehta"},{"key":"10.1038\/gim.2012.39_bb0030","author":"MacDermot"},{"key":"10.1038\/gim.2012.39_bb0035","author":"European FOS Investigators"},{"key":"10.1038\/gim.2012.39_bb0040","author":"FOS Investigators"},{"key":"10.1038\/gim.2012.39_bb0045","author":"Lidove"},{"key":"10.1038\/gim.2012.39_bb0050","author":"Hoffmann"},{"key":"10.1038\/gim.2012.39_bb0055","unstructured":"EMEA. Assessment report on the shortage of Fabrazyme. Overview of Shortage Period: Spontaneous Reports from June 2009 through 15 September 2010 and Registry Data from June 2009 through 05 August 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2010\/11\/WC500099241.pdf. Accessed September 2011."},{"key":"10.1038\/gim.2012.39_bb0060","author":"Sirrs"},{"key":"10.1038\/gim.2012.39_bb0065","author":"European Medicines Agency"},{"key":"10.1038\/gim.2012.39_bb0070","author":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)"},{"key":"10.1038\/gim.2012.39_bb0075","author":"Devereux"},{"key":"10.1038\/gim.2012.39_bb0080","author":"Lang"},{"key":"10.1038\/gim.2012.39_bb0085","author":"Tan"},{"key":"10.1038\/gim.2012.39_bb0090","author":"The EuroQoL Group"},{"key":"10.1038\/gim.2012.39_bb0095","author":"Whybra"},{"key":"10.1038\/gim.2012.39_bb0100","author":"Smid"},{"key":"10.1038\/gim.2012.39_bb0105","author":"Fabry Outcome Survey investigators"},{"key":"10.1038\/gim.2012.39_bb0110","author":"Linthorst"},{"key":"10.1038\/gim.2012.39_bb0115","doi-asserted-by":"crossref","unstructured":"Tanaka A, Takeda T, Hoshina T,et al. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha. J Inherit Metab Dis 2010; e-pub ahead of print 22 June 2010.","DOI":"10.1007\/s10545-010-9136-0"}],"updated-by":[{"DOI":"10.1038\/gim.2012.62","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000}}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/gim201239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gim201239","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360021045342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360021045342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gim201239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T15:13:11Z","timestamp":1691680391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360021045342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1098360021045342"],"URL":"https:\/\/doi.org\/10.1038\/gim.2012.39","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/gim.2012.39","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics","name":"copyright","label":"Copyright"}]}}